Prot #CRLX030A2301: A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients

  • Courtney, D Mark (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/1/136/30/17

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CRLX030A2301)